Oppenheimer Reiterates Outperform on BioLife Solns, Maintains $28 Price Target
Oppenheimer analyst Suraj Kalia reiterates BioLife Solns (NASDAQ:BLFS) with a Outperform and maintains $28 price target.
BioLife Solutions Expands Intellectual Property Estate
7 New Granted Patents; 43 Submitted Patent Applications
Global Portfolio Now Totals 148 Issued and 114 Pending Patents
BioLife Solutions, Inc. (NASDAQ:BLFS) ("BioLife" or the "Company"), a
Why Magnite Shares Are Trading Higher By Over 45%? Here Are 69 Stocks Moving In Thursday’s Mid-Day Session
Gainers
Fast Radius, Inc. (NASDAQ: FSRD) shares climbed 172% to $0.2769 after dipping 40% on Wednesday. Fast Radius received Bankruptcy court approval of first day motions related to the company's voluntary Chapter 11 petitions filed on November 7.
BioLife Solns: Q2 Earnings Insights
BioLife Solns (NASDAQ:BLFS) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:00 PM.
Here's what investors need to know about the announcement.
Earnings Scheduled For August 9, 2022
Companies Reporting Before The Bell
• Cognition Therapeutics (NASDAQ:CGTX) is estimated to report earnings for its second quarter.
Stephens & Co. Maintains Overweight on BioLife Solns, Lowers Price Target to $40
Stephens & Co. analyst Jacob Johnson maintains BioLife Solns (NASDAQ:BLFS) with a Overweight and lowers the price target from $47 to $40.
